SINT

Sintx Technologies Inc

3.83

-0.10-2.54%

After Hours: 3.830 0.00 0.00%17:58 01/08 EST

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE3.970/3.930

TODAY RANGE3.750-4.140

VOL92.04K

MARKET CAP14.75M

52 WEEK RANGE1.710-7.36

AVG VOL (3M)181.77K

% TURNOVER2.39%

TURNOVER--

P/E (TTM)-0.5529

% RANGE9.67%

EPS(TTM)-6.9268

P/E(FORWARD)-0.6320

P/B3.404

BVPS1.125

DIVIDEND--

P/S1.781

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP12.24M

SHARES OUTSTANDING3.85M

NEXT EARNINGS03/17-03/23

FREE FLOAT3.19M

LOT SIZE1

EX-DATE05/28/2024

News

Press Releases

Financial Reports

Profile

TipRanks·12/10/2025 02:08
CIO Makes Bold Move with Major Stock Purchase in Sintx Technologies
Reuters·12/09/2025 13:00
Gregg R. Honigblum, Chief Investment Officer, acquires common shares of SINTX Technologies Inc
Reuters·12/08/2025 13:00
SINTX Technologies Inc. Chief Investment Officer Gregg R. Honigblum Acquires Common Shares
Dow Jones·12/08/2025 10:41
SiNtx Technologies Price Target Cut to $16.00/Share From $25.00 by Ascendiant Capital
Dow Jones·12/08/2025 10:41
SiNtx Technologies Is Maintained at Buy by Ascendiant Capital
TipRanks·12/01/2025 13:35
Sintx Technologies signs supply agreement with EVONIK
Reuters·12/01/2025 13:30
SINTX Technologies Signs Supply Agreement With Evonik for Silicon Nitride–PEEK Implant Production
Reuters·12/01/2025 13:30
SINTX TECHNOLOGIES SIGNS SUPPLY AGREEMENT WITH EVONIK TO MANUFACTURE SILICON NITRIDE–PEEK COMPOUND FOR AI-ASSISTED, 3D-PRINTED PATIENT-SPECIFIC IMPLANTS
Seeking Alpha·11/13/2025 17:16
Sintx Technologies GAAP EPS of -$3.46 misses by $2.95, revenue of $0.21M misses by $0.09M
Reuters·11/13/2025 13:09
Biomaterials firm SINTX misses Q3 revenue estimates
Reuters·11/13/2025 13:06
SINTX Technologies posts Q3 net loss of $3.5 million on first OsseoSculpt revenue
Dow Jones·11/13/2025 13:03
*SiNtx Technologies 3Q Rev $208,000 Vs. $799,000 >SINT
Dow Jones·11/13/2025 13:03
*SiNtx Technologies 3Q Loss/Shr $3.46 >SINT
Reuters·11/13/2025 13:00
SINTX REPORTS PIVOTAL THIRD QUARTER BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS DRIVEN BY FDA CLEARANCE, PRODUCT AND IP PORTFOLIO EXPANSIONS AND INCREASED OPERATIONAL EFFICIENCIES
Reuters·11/13/2025 13:00
SINTX TECHNOLOGIES, INC. Q3 REVENUE USD 200 THOUSAND

Same Industry

Name/Symbol

Change%

Price

Sintx Technologies Inc

SINT

-2.54%

3.83

Atrion Corp

ATRI

0.00%

459.92

IDEXX Laboratories

IDXX

-0.30%

712.39

Cencora Inc.

COR

-1.37%

335.74

Teleflex Inc

TFX

-13.06%

110.01

Stryker Corp

SYK

-0.15%

367.21

West Pharm Svcs

WST

-1.15%

275.23

Ufp Technologies

UFPT

+2.38%

255.42

Shockwave Medical, Inc.

SWAV

0.00%

334.75

Cooper

COO

-0.92%

83.13

Becton Dickinson & Co

BDX

+1.22%

205.18

Becton Dickinson And Co

BDXB

48.16

Utah Med Prods

UTMD

+1.78%

58.73

Align Technology Inc

ALGN

+2.26%

170.58

Henry Schein

HSIC

+1.10%

79.00

Ge Healthcare Technologies Inc

GEHC

+2.80%

88.16

Repligen

RGEN

-1.56%

166.42

Abbott Labs

ABT

-0.68%

126.18

Conmed Corp

CNMD

+1.84%

44.20

Medtronic

MDT

-1.08%

98.69

Zimmer Biomet

ZBH

+1.52%

94.08

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.